Literature DB >> 23102561

Opioid switching in patients with advanced cancer followed at home. A retrospective analysis.

Sebastiano Mercadante1, Alessandro Valle, Giampiero Porzio, Flavio Fusco, Federica Aielli, Claudio Adile, Alessandra Casuccio.   

Abstract

CONTEXT: Opioid switching has been found to improve opioid responsiveness in different conditions. However, data on opioid switching performed at home are almost nonexistent, despite the fact that most patients are followed at home.
OBJECTIVES: The aim of this retrospective survey was to determine frequency, indications, usefulness, and safety of opioid switching when treating advanced cancer-related pain in patients followed at home.
METHODS: A retrospective review of data from patients with advanced cancer followed at home by three home care teams for a period of two years was performed. Patients who had their opioids switched were selected. Reasons for switching opioid doses and routes of administration and outcomes were collected.
RESULTS: Two hundred one (17%) of 1141 patients receiving "strong" opioids were switched. The mean Karnofsky Performance Status score was 35.6, and the median survival was 30 days. The most frequent reason to switch was for convenience, and the most frequent switch was to parenteral morphine. In most patients, a better analgesic response was observed. Patients who were switched to parenteral morphine had a shorter survival in comparison with other opioid sequences (P<0.0005). After switching, opioid doses were increased by 23% and 41%, after a week and at time of death, respectively.
CONCLUSION: Opioid switching was useful for most patients in the home environment, at least in less complex circumstances, when done by experienced home care teams. Prospective studies are needed to provide information about the decision to admit to hospital for this purpose and the predictive factors that may relatively contraindicate transportation to a facility in severely ill patients.
Copyright © 2013 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23102561     DOI: 10.1016/j.jpainsymman.2012.02.025

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  6 in total

1.  The poor use of methadone in Italian hospices.

Authors:  Sebastiano Mercadante; Alessandro Valle; Cristina Agnelotti; Amanda Caruselli
Journal:  Support Care Cancer       Date:  2013-03-16       Impact factor: 3.603

2.  Efficacy and Safety of Methadone as a Second-Line Opioid for Cancer Pain in an Outpatient Clinic: A Prospective Open-Label Study.

Authors:  Josep Porta-Sales; Cristina Garzón-Rodríguez; Christian Villavicencio-Chávez; Silvia Llorens-Torromé; Jesús González-Barboteo
Journal:  Oncologist       Date:  2016-06-15

3.  Opioid switching and variability in response in pain cancer patients.

Authors:  O Corli; A Roberto; N Corsi; F Galli; M Pizzuto
Journal:  Support Care Cancer       Date:  2018-10-24       Impact factor: 3.603

4.  The use of rotation to fentanyl in cancer-related pain.

Authors:  Delia Dima; Ciprian Tomuleasa; Ioana Frinc; Sergiu Pasca; Lorand Magdo; Ioana Berindan-Neagoe; Mihai Muresan; Cosmin Lisencu; Alexandru Irimie; Mihnea Zdrenghea
Journal:  J Pain Res       Date:  2017-02-09       Impact factor: 3.133

5.  Managing cancer pain at the end of life with multiple strong opioids: a population-based retrospective cohort study in primary care.

Authors:  Wei Gao; Martin Gulliford; Michael I Bennett; Fliss E M Murtagh; Irene J Higginson
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

Review 6.  Transdermal buprenorphine and fentanyl patches in cancer pain: a network systematic review.

Authors:  Jin Seok Ahn; Johnson Lin; Setsuro Ogawa; Chen Yuan; Tony O'Brien; Brian Hc Le; Andrea M Bothwell; Hanlim Moon; Yacine Hadjiat; Abhijith Ganapathi
Journal:  J Pain Res       Date:  2017-08-18       Impact factor: 3.133

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.